Blue Matter Blog

Panel Discussion Video: The Renaissance of Psychedelics in CNS Medicine
September 16, 2021

On September 9, 2021 at the MedInvest Neurological Diseases & Mental Health Disorders Conference, our own Varun Renjen moderated a panel discussion entitled, The Renaissance of Psychedelics in CNS Medicine.  This video includes the full panel discussion and the Q&A session following it. Thanks very much to all of our panelists for their expertise and …

Spinal Muscular Atrophy: A Rare Disease with a Complex Treatment Landscape (Part 1)
August 18, 2021

The Spinal Muscular Atrophy (SMA) treatment landscape offers a compelling case study of how very different therapeutic approaches can be successful in alleviating a devastating rare disease, leading to a complex treatment landscape with continued opportunity for both improved patient outcomes and biopharma market success. Here in Part 1, we introduce the disease and its …

How will the change to a more narrow FDA label for Aduhelm (aducanumab) help Biogen?
July 14, 2021

Varun Renjen, M.D. describes how the recent decision to restrict Aduhelm’s label to earlier-stage patients with mild cognitive impairment (MCI) could be a good thing for Biogen’s new Alzheimer’s therapy. He also outlines three lessons for other pharma companies entering the Alzheimer’s market. Link here

What challenges could Biogen’s Aduhelm (aducanumab) face as it goes to market?
June 28, 2021

Biogen’s Aduhelm® (aducanumab) is the fist potentially disease-modifying therapy approved for Alzheimer’s disease.  However, it could face some significant challenges as it goes to market. Varun Renjen, M.D., describes the three main ones in this short video. Link here.

What impact is Biogen’s Aduhelm (aducanumab) likely to have on the Alzheimer’s Market?
June 24, 2021

On June 7, 2021, the FDA approved Biogen’s Aduhelm® (aducanumab) for Alzheimer’s disease.  As the first potentially disease-modifying therapy for Alzheimer’s, it could have some significant impacts on the market for Alzheimer’s therapies. Varun Renjen, M.D., outlines those potential impacts in this short video. Link here

Upcoming Webinar: Psychedelics in CNS Therapeutics
June 21, 2021

Don’t miss this informative webinar on Tuesday, July 20 at 11:00 am EDT. Register here. Psychedelics and other traditionally taboo substances are undergoing a bit of a “renaissance” in central nervous system (CNS) therapeutics. These types of substances have a long and storied history around the world. Now, research into their potential therapeutic benefits is …

Alzheimer’s Disease: An In-Depth Look at a Formidable Foe
June 8, 2021

There is no shortage of disabling and deadly diseases in the world.  However, few match Alzheimer’s disease (AD) when it comes to sheer ability to cause fear and dread.  It’s not a rare disease.  In fact, it’s on the rise.  There is no cure (nor effective treatment yet) and it’s ultimately fatal.  And, most frightening, …

Recap:  Psychedelic Therapeutics and Drug Development Conference
May 25, 2021

Introduction Members of Blue Matter’s CNS team attended the Psychedelic Therapeutics & Drug Development Conference, a virtual event that took place May 4-6, 2021.  This event was particularly interesting to our team because we had just completed a white paper entitled “Taboo” Substances are Getting Another Look in CNS that explored the substances and companies …

American Academy of Neurology (AAN) 2021: Annual Meeting Recap
May 24, 2021

Introduction Members of our CNS team attended the American Academy of Neurology (AAN) virtual annual meeting, which took place April 17-22. As expected, it was an interesting and useful event, full of industry therapeutics updates, clinical research data, scientific sessions, and educational courses presented in a series of virtual panels, posters, and fireside chats.  It …

“Taboo” Substances Are Getting Another Look in CNS
March 22, 2021

Psychedelics and other traditionally taboo substances appear to be undergoing a bit of a “renaissance” in central nervous system (CNS) therapeutics these days.  These types of substances have a long and storied history all around the world.  Now, science is getting serious about exploring ways to use them to treat a range of diseases and …

Central Nervous System Therapies: Outlook for 2021 & Beyond
January 5, 2021

So far in this series, we’ve spent a great deal of time looking backward.  In part 1, we discussed the “quiet revolution” that has been taking place in CNS over the past several years.  Interesting advances are being made in a range of CNS therapies while other areas, such as oncology, tend to get more …

Central Nervous System Therapies: A Look at Rising Investment Activity
December 15, 2020

In Part 1 of this series, we said that a “quiet revolution” has been taking place in central nervous system (CNS) therapies.  While much attention has been focused on the dramatic advancements in oncology, companies large and small have been focusing more resources on CNS research, and the pace of advancement is accelerating.  In that …

Central Nervous System Therapies: Where We’ve Been and the Road Ahead
November 16, 2020

“Life moves pretty fast. If you don’t stop and look around once in a while, you could miss it.” Some readers might recognize that as a memorable line from the ‘80’s classic movie, Ferris Bueller’s Day Off.  Those same readers might also ask what it has to do with central nervous system (CNS) therapies. In …